娇生以140亿美元收购Intra-Cellular Therapies,强化其在脑部健康领域的展望,此收购案将带来Caplyta,预计该药物将在数种神经系统疾病领域成为畅销药。其他并购新闻方面,葛兰素史克和礼来分别达成协议,以充实其癌症药物管线。 J&J Bolsters Its Prospects in Brain Health With $14B Buyout of Intra-Cellular Therapies一文最早刊登于MedCity News。
#Johnson & Johnson, Intra-Cellular Therapies, GSK, Eli Lilly
Newsflash | Powered by GeneOnline AI
原始资料来源: Frank Vinluan 14 Jan 2025 00:33:52